Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Vimta Labs Limited is a comprehensive contract research and testing organization serving industries like pharmaceuticals, food, electronics, and environment testing. With expertise in drug discovery and development, it offers pivotal support for numerous sectors.
The company has experienced a commendable 10.2% year-on-year revenue growth as of Q3 FY26, showcasing resilience and effective market penetration. The diverse testing services offered have significantly contributed to these earnings.
Strategic capacity expansion, especially in biologics and electronics sectors, hints at Vimta Labs Limited's commitment to seize emerging opportunities, reflecting a calculated approach to maximize its operational footprint.
International business continues to bolster Vimta Labs Limited's financial trajectory, with exports contributing around 39% of their income, underscoring its strong global presence, particularly in pharmaceutical analytical services.
Healthcare Services
Healthcare Research, Analytics & Technology
2,138 Cr
Low Risk
34.8
56.4
0.7
6.2
902.85
372.50
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
408.05 | 2,138 Cr | 34.83 | 6.24 | 0.21 | 14.59 | 19.04 | 13.94 | ||
46.04 | 641 Cr | 398.23 | 24.85 | 0.00 | 15.55 | 21.32 | 4.57 | ||
64.02 | 158 Cr | -51.37 | 2.48 | 0.00 | -9.29 | -5.26 | -2.47 | ||
57.69 | 144 Cr | -12.50 | 0.32 | 0.00 | -2.81 | 0.93 | -2.96 | ||
17.03 | 82 Cr | 328.72 | 1.51 | 0.00 | 1.03 | 3.26 | 0.36 | ||
50.29 | 59 Cr | -27.02 | 3.24 | 0.00 | -30.18 | -32.45 | -30.18 | ||
16.98 | 22 Cr | 12.47 | 1.44 | 0.00 | 0.00 | 0.00 | 2.57 | ||
| Median: 7 Co. | — | 50.29 | 144 Cr | 12.47 | 2.48 | 0.00 | 0.00 | 0.93 | 0.36 |
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Upcoming Result Date: May 05, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Vimta Labs Ltd (VIMTALABS) is currently trading at 456.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Vimta Labs Limited is a comprehensive contract research and testing organization serving industries like pharmaceuticals, food, electronics, and environment testing. With expertise in drug discovery and development, it offers pivotal support for numerous sectors. The company has experienced a commendable 10.2% year-on-year revenue growth as of Q3 FY26, showcasing resilience and effective market penetration. The diverse testing services offered have significantly contributed to these earnings. Strategic capacity expansion, especially in biologics and electronics sectors, hints at Vimta Labs Limited's commitment to seize emerging opportunities, reflecting a calculated approach to maximize its operational footprint. International business continues to bolster Vimta Labs Limited's financial trajectory, with exports contributing around 39% of their income, underscoring its strong global presence, particularly in pharmaceutical analytical services.
Over the past 52 weeks, Vimta Labs Ltd has traded between a low of ₹372.50 and a high of ₹902.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Vimta Labs Ltd has a market capitalization of approximately 2,137.65. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Vimta Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 34.83 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,137.65 Cr, Vimta Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Vimta Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Vimta Labs Ltd is 34.83. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
3
Neutral
6
Bullish
5
Bearish
19
Neutral
6
Bullish
21
Bearish
16
Neutral
0
Bullish
16
Analyst/Investor Call
Vimta Labs scheduled an analyst/investor conference call on 6 May 2026 at 4:30 PM IST to discuss Q4 FY2025-26 financial results; dial-in numbers and DiamondPass registration provided.
Board Meeting - Financial Results
Vimta Labs will meet on 06-May-2026 to consider and approve audited Q4 and FY2025-26 financial results and may recommend a final dividend; trading window closed from 01-Apr-2026 until 48 hours after results.
Shareholder Notice
Vimta Labs published a shareholder notice informing transfer of FY2018-19 unclaimed dividend and corresponding shares to IEPF, requesting KYC/bank/email updates, opening a special demat/transfer window and launching the Saksham Niveshak campaign.
